Paracrine to Present at Biotech Showcase™ 2022

Paracrine, Inc. announced today that it is presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation which is now accessible. This year, registered attendees to Biotech Showcase can access Paracrine’s recorded company presentation on-demand.

Paracrine is an emerging biotechnology company developing a first-in-class, device-based, autologous cell therapy. Paracrine’s cell therapy platform bears the promise of cost-effectively addressing common, underlying pathology of several debilitating chronic diseases due to its unique multi-prong mechanisms of action. The company has an FDA approved IDE for the pivotal ASCEND Trial in patients with non-healing diabetic foot ulcers, the STAR II pivotal trial IDE is currently under review at FDA for hand dysfunction due to scleroderma and an IDE is being prepared for submission later this year for the ATHENA III trial in patients with chronic heart failure … read more